17-hydroxy-6,18-dimethoxy-3,11,12,13,14,15,16,17,18,19,20,21-dodecahydro-1H-yohimban-13-ium-19-carboxylate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 柯楠因类生物碱
• 英文名称: 17-hydroxy-6,18-dimethoxy-3,11,12,13,14,15,16,17,18,19,20,21-dodecahydro-1H-yohimban-13-ium-19-carboxylate
• 化学式: C22H28N2O5
• 分子量: 400.5
• InChiKey: JVHNBFFHWQQPLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  95
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Assays for identification of topoisomerase inhibitors
  申请人：Stivers T. James

  公开号：US20080020973A1

  公开（公告）日：2008-01-24

  The instant invention provides a continuous spectroscopic assay for DNA topoisomerase activity. The invention further provides topoisomerase inhibitors and pharmaceutical compositions for the treatment of topoisomerase associated diseases and disorders.
• INDOLE ALKALOID COMPOUNDS AS MELANOGENESIS PROMOTERS AND USES THEREOF
  申请人：Orlow Seth J.

  公开号：US20130302264A1

  公开（公告）日：2013-11-14

  Provided are indole alkaloid compounds of formula I, for example, pubescine, and the use of such compounds and compositions thereof to promote (e.g., enhance) melanogenesis and pigmentation. Also provided are plant extracts containing a compound of formula I, for example, pubescine, and the use of such a plant extract to promote (e.g., enhance) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.
• US9138433B2
  申请人：——

  公开号：US9138433B2

  公开（公告）日：2015-09-22
• [EN] COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME<br/>[FR] MODES DE RÉALISATION DE COMPOSÉ POUR LE TRAITEMENT DE LA DÉGÉNÉRESCENCE RÉTINIENNE ET MODES DE RÉALISATION DE PROCÉDÉ DE PRÉPARATION ET DE MÉTHODES D'UTILISATION DE CELUI-CI
  申请人：US HEALTH

  公开号：WO2022006439A2

  公开（公告）日：2022-01-06

  Method embodiments are disclosed for treating retinal degeneration in a subject in need thereof. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of compound, and/or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, or tautomer thereof, selected from 3-(dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride or a compound having a structure according to a formula selected from Formula I, II, or III, as described herein. In some non-limiting examples, the subject has retinitis pigmentosa, LCA, Stargardt's macular dystrophy, cone-rod dystrophy, choroideremia or age-related macular degeneration.